Real-life treatment outcomes of ravulizumab in PNH - PNH-RECORD

Study identifier:D9289R00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

Real-life treatment outcomes of ravulizumab in Polish patients with paroxysmal nocturnal hemoglobinuria (PNH). Prospective and retrospective, multicenter, non-interventional study.

Medical condition

Paroxysmal nocturnal haemoglobinuria

Phase

N/A

Healthy volunteers

Study drug

Ravulizumab

Sex

All

Estimated Enrollment

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 31 Jan 2025

Estimated Primary Completion Date: 01 Aug 2028

Estimated Study Completion Date: 01 Aug 2028

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Ravulizumab group Open-label	-

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]